Back to search results
Adam L. Boxer
Adam L. Boxer

Adam L. Boxer, MD, PHD

Neurology

Memory and Aging Center
1651 Fourth St., Suite 212,
San Francisco, CA 94158
(415) 353-2057
Virtual visits available
Virtual visits available
Memory and Aging Center
1651 Fourth St., Suite 212,
San Francisco, CA 94158
(415) 353-2057

Dr. Adam Boxer is a neurologist at the UCSF Memory and Aging Center who specializes in Alzheimer's disease, frontotemporal dementia and atypical parkinsonism – in particular, corticobasal degeneration and progressive supranuclear palsy.

Boxer obtained his medical and doctoral degrees as part of the Medical Scientist Training Program at New York University School of Medicine, a program funded by the National Institutes of Health. He completed a residency in neurology at Stanford University Medical Center and a fellowship in behavioral neurology at UCSF.

Boxer directs the clinical neurology research unit for the Sandler Neurosciences Center at Mission Bay, as well as the clinical trials program for Alzheimer's disease and frontotemporal dementia at the Memory and Aging Center.

Boxer received the Edwin Boldrey Award from the San Francisco Neurological Society in 2002 for basic research in neurological disease, the 2005 John Douglas French Alzheimer's Foundation Alzheimer's Award and a 2009 Hellman Family Foundation fellowship.

  • Board Certifications

    American Board of Psychiatry and Neurology, Neurology

  • Fellowships

    UCSF, Neurobehavior

  • Degree

    MD, NYU Grossman School of Medicine

We empower patients and their families to access cutting-edge diagnostic and therapeutic technologies for neurodegenerative diseases of aging.

Conditions I specialize in

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    The Progressive Supranuclear Palsy Clinical Trial Platform

    Change in disease severity as measured by the 15-item modified Progressive Supranuclear Palsy Rating Scale (mPSPRS-15) in which the minimum score is 0 and the maximum score is 52, with higher scores indicating a worse outcome.

    Recruiting

    Decorative Caduceus

    Alzheimer's Tau Platform: Master Protocol

    To determine whether at least one tau therapy, either alone or in combination with an anti-amyloid monoclonal antibody (mAb), will produce a greater reduction in brain tau deposition as measured by 18F-MK-6240 PET compared to anti...

    Recruiting

    Decorative Caduceus

    Alzheimer's Tau Platform: Regimen A - AADvac1

    To determine whether at least one tau therapy, either alone or in combination with an anti-amyloid mAb, will produce a greater reduction in brain tau deposition as measured by 18F-MK-6240 PET compared to anti-amyloid mAb alone.

    Recruiting

    Decorative Caduceus

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    Compare rates of change in whole brain and regional volumes between asymptomatic f-FTLD and symptomatic f- and s-FTLD, measured using MRI.

    Recruiting

    Contact me

    Share